A Phase 1 Randomized, Placebo-Controlled, Double-Blind Study of the Safety, Tolerability and Pharmacological Effects of PT00114 in Healthy Volunteers

2024-519316-13-00 Protocol PT00114-001A Human pharmacology (Phase I) - First administration to humans Ended

Start 1 Aug 2025 · End 24 Sep 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol PT00114-001A

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 24
Countries 1
Sites 1

Phase I study in healthy male and female volunteers. Intended indication: mood disorders

Key facts

Sponsor
Protagenic Therapeutics Inc.
Participant type
Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Psychiatry and Psychology [F] - Mental Disorders [F03]
Trial duration
1 Aug 2025 → 24 Sep 2025
Decision date (initial)
2025-07-02
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Phase I study in healthy male and female volunteers. Intended indication: mood disorders

VersionLevelCodeTermSystem organ class
20.0 PT 10057666 Anxiety disorder 100000004873
21.1 PT 10036316 Post-traumatic stress disorder 100000004873
20.1 LLT 10079614 Mood disorder 10037175

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Protagenic Therapeutics Inc.

Sponsor organisation
Protagenic Therapeutics Inc.
Address
149 5th Avenue Suite 500
City
New York
Postcode
10010-6826
Country
United States

Scientific contact point

Organisation
Protagenic Therapeutics Inc.
Contact name
Andrew Slee

Public contact point

Organisation
Protagenic Therapeutics Inc.
Contact name
Andrew Slee

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 24 1
Rest of world 0

Investigational sites

Germany

1 site · Ended
Nuvisan GmbH
Clinical Services, Wegenerstrasse 13, Ludwigsfeld, Neu-Ulm

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2025-08-01 2025-09-24 2025-08-01 2025-08-01

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-04-29 Germany Acceptable
2025-07-01
2025-07-02
2 SUBSTANTIAL MODIFICATION SM-1 2025-07-15 Germany Acceptable 2025-07-24